FI951250L - Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot - Google Patents

Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot Download PDF

Info

Publication number: FI951250L
Authority: FI; Finland
Prior art keywords: interleukin; inhibitors; pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 1992-09-17

Application number

FI951250A

Other languages

English (en)

Swedish (sv)

Other versions

FI951250A0 (fi

FI951250A7 (fi

Inventor

Benjamin K Sabados

Original Assignee

Amgen Boulder Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-17

Filing date

1993-09-17

Publication date

1995-03-16

1993-09-17 Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc

1995-03-16 Publication of FI951250L publication Critical patent/FI951250L/fi

1995-03-16 Publication of FI951250A0 publication Critical patent/FI951250A0/fi

1995-03-16 Publication of FI951250A7 publication Critical patent/FI951250A7/fi

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

FI951250A 1992-09-17 1993-09-17 Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot FI951250A7 (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94700692A	1992-09-17	1992-09-17
PCT/US1993/008802 WO1994006457A1 (en)	1992-09-17	1993-09-17	Pharmaceutical formulations of interleukin-1 inhibitors

Publications (3)

Publication Number	Publication Date
FI951250L true FI951250L (fi)	1995-03-16
FI951250A0 FI951250A0 (fi)	1995-03-16
FI951250A7 FI951250A7 (fi)	1995-03-16

Family

ID=25485348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI951250A FI951250A7 (fi)	1992-09-17	1993-09-17	Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot

Country Status (19)

Country	Link
EP (1)	EP0661992B1 (fi)
JP (1)	JP3626755B2 (fi)
KR (1)	KR950703358A (fi)
AT (1)	ATE257389T1 (fi)
AU (1)	AU675969B2 (fi)
CA (1)	CA2141953C (fi)
CZ (1)	CZ291261B6 (fi)
DE (1)	DE69333378T2 (fi)
DK (1)	DK0661992T3 (fi)
ES (1)	ES2213744T3 (fi)
FI (1)	FI951250A7 (fi)
HU (1)	HU219445B (fi)
NO (1)	NO321453B1 (fi)
NZ (1)	NZ256328A (fi)
PL (1)	PL175705B1 (fi)
PT (1)	PT661992E (fi)
RO (1)	RO113528B1 (fi)
RU (1)	RU2126262C1 (fi)
WO (1)	WO1994006457A1 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
AU2063197A (en) *	1996-03-04	1997-09-22	Massachusetts Institute Of Technology	Materials and methods for enhancing cellular internalization
WO1998024477A1 (en)	1996-12-06	1998-06-11	Amgen Inc.	Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013253A (en) *	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
RU2153352C1 (ru) *	1999-08-09	2000-07-27	Гончар Александр Михайлович	Фармацевтическая композиция, обладающая ранозаживляющим и противовоспалительным действием
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
ITMI20010206A1 (it) *	2001-02-02	2002-08-02	Dompe Spa	Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
CN103232539B (zh)	2001-06-26	2015-06-03	安姆根弗里蒙特公司	抗opgl抗体
JP4610154B2 (ja) *	2002-05-30	2011-01-12	大塚製薬株式会社	注射用製剤
CN104178491B (zh)	2002-09-06	2018-07-03	安姆根有限公司	治疗性人抗-il-1r1单克隆抗体
RS57852B1 (sr) *	2004-04-02	2018-12-31	Swedish Orphan Biovitrum Ab Publ	Postupci za smanjenje agregacije il-1ra
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP2008120722A (ja) *	2006-11-10	2008-05-29	Benesis Corp	生物由来製品の偽薬
WO2009062339A1 (en)	2007-11-14	2009-05-22	General Regeneratives, Ltd.	Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
WO2009100406A2 (en) *	2008-02-07	2009-08-13	Synta Pharmaceuticals Corp.	Topical formulations for the treatment of psoriasis
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
CA2779088A1 (en)	2009-11-16	2011-05-19	Mellitech	[1,5]-diazocin derivatives
EP2598526B1 (en)	2010-07-29	2018-09-05	Eleven Biotherapeutics, Inc.	Chimeric il-1 receptor type i agonists and antagonists
WO2012078101A1 (en) *	2010-12-07	2012-06-14	Swedish Orphan Biovitrum Ab (Publ)	Method for the treatment of il-1 mediated diseases
LT2672985T (lt)	2011-02-11	2016-10-10	Swedish Orphan Biovitrum Ab (Publ)	Citrato neturinčios farmacinės kompozicijos, apimančios anakinrą
WO2013016220A1 (en)	2011-07-22	2013-01-31	Amgen Inc.	Il-17 receptor a is required for il-17c biology
JP2014522868A (ja) *	2011-07-29	2014-09-08	イレブン・バイオセラピユーテイクス・インコーポレイテツド	精製タンパク質
JP6450364B2 (ja)	2013-03-13	2019-01-09	セセンバイオ，インコーポレイテッド	眼送達のためのキメラサイトカイン製剤
WO2015191783A2 (en)	2014-06-10	2015-12-17	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
US10751426B2 (en)	2015-10-30	2020-08-25	Bonac Corporation	Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
WO2018022982A1 (en)	2016-07-29	2018-02-01	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
ES3030707T3 (en)	2018-08-13	2025-07-01	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20250283174A1 (en)	2022-05-16	2025-09-11	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
US20260015427A1 (en)	2024-06-25	2026-01-15	Kiniksa Pharmaceuticals, Gmbh	Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5416568B2 (fi) *	1972-09-29	1979-06-23
JPS537491B2 (fi) *	1972-09-30	1978-03-18
AU9106491A (en) *	1991-01-17	1992-08-27	Upjohn Company, The	Method of preventing and treating insulin dependent diabetes mellitus

1993
- 1993-09-17 NZ NZ256328A patent/NZ256328A/en not_active IP Right Cessation
- 1993-09-17 DE DE69333378T patent/DE69333378T2/de not_active Expired - Lifetime
- 1993-09-17 PL PL93308543A patent/PL175705B1/pl unknown
- 1993-09-17 PT PT93921651T patent/PT661992E/pt unknown
- 1993-09-17 ES ES93921651T patent/ES2213744T3/es not_active Expired - Lifetime
- 1993-09-17 CZ CZ1995643A patent/CZ291261B6/cs not_active IP Right Cessation
- 1993-09-17 JP JP50833894A patent/JP3626755B2/ja not_active Expired - Lifetime
- 1993-09-17 WO PCT/US1993/008802 patent/WO1994006457A1/en not_active Ceased
- 1993-09-17 CA CA002141953A patent/CA2141953C/en not_active Expired - Lifetime
- 1993-09-17 HU HU9500790A patent/HU219445B/hu unknown
- 1993-09-17 DK DK93921651T patent/DK0661992T3/da active
- 1993-09-17 KR KR1019950701028A patent/KR950703358A/ko not_active Ceased
- 1993-09-17 EP EP93921651A patent/EP0661992B1/en not_active Expired - Lifetime
- 1993-09-17 RO RO95-00540A patent/RO113528B1/ro unknown
- 1993-09-17 FI FI951250A patent/FI951250A7/fi unknown
- 1993-09-17 RU RU95109908A patent/RU2126262C1/ru active
- 1993-09-17 AU AU49276/93A patent/AU675969B2/en not_active Expired
- 1993-09-17 AT AT93921651T patent/ATE257389T1/de active
1995
- 1995-03-15 NO NO19951006A patent/NO321453B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO951006L (no)	1995-03-15
NZ256328A (en)	1997-06-24
DE69333378D1 (de)	2004-02-12
DK0661992T3 (da)	2004-04-05
EP0661992A1 (en)	1995-07-12
ES2213744T3 (es)	2004-09-01
JP3626755B2 (ja)	2005-03-09
PL308543A1 (en)	1995-08-21
EP0661992B1 (en)	2004-01-07
FI951250A0 (fi)	1995-03-16
NO951006D0 (no)	1995-03-15
FI951250A7 (fi)	1995-03-16
PT661992E (pt)	2004-05-31
DE69333378T2 (de)	2004-07-01
CZ291261B6 (cs)	2003-01-15
WO1994006457A1 (en)	1994-03-31
CA2141953A1 (en)	1994-03-31
AU4927693A (en)	1994-04-12
ATE257389T1 (de)	2004-01-15
AU675969B2 (en)	1997-02-27
KR950703358A (ko)	1995-09-20
RO113528B1 (ro)	1998-08-28
JPH08504755A (ja)	1996-05-21
CA2141953C (en)	2008-04-08
PL175705B1 (pl)	1999-01-29
NO321453B1 (no)	2006-05-15
RU2126262C1 (ru)	1999-02-20
HU9500790D0 (en)	1995-05-29
CZ64395A3 (en)	1995-10-18
HU219445B (hu)	2001-04-28
HUT71679A (en)	1996-01-29

Publication	Publication Date	Title
FI951250L (fi)	1995-03-16	Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot
FI953515L (fi)	1996-01-21	Fluoksetiinin farmaseuttiset formulaatiot
DK0585252T3 (da)	2001-11-12	Farmaceutiske formuleringer
DK481989D0 (da)	1989-09-29	Farmaceutiske formuleringer
BR9610153A (pt)	1999-01-05	Formulações farmacêuticas
BR9500784A (pt)	1995-10-24	Composto e formulação farmacêutica
BR9611626A (pt)	1999-06-01	Formulações farmacéuticas
BR9504060A (pt)	1996-09-24	Composto e formulação farmacêutica
PT769965E (pt)	2002-04-29	Formulacoes aquosas de risperidona
BR1100329A (pt)	2000-06-13	Composto e formulação farmacêutica
FI930882A0 (fi)	1993-02-26	Farmaceutiska foereningar
FI950402A7 (fi)	1995-01-30	Oraaliset koostumukset
ITMI921123A0 (it)	1992-05-11	Formulazioni farmaceutiche orali contenenti antocianosidi
FI961521L (fi)	1996-04-04	Lääkeformulaatioiden valmistusmenetelmä
FI953887L (fi)	1996-06-14	Kefaklorin farmaseuttisia formulaatioita
ITMI921413A0 (it)	1992-06-08	Preparazioni farmaceutiche stabili di nicorandil
IT1276799B1 (it)	1997-11-03	Formulazioni di f-silicone
FI931251A0 (fi)	1993-03-22	Farmaceutiska foereningar
ITMI941169A0 (it)	1994-06-06	Formulazioni farmaceutiche
NO951933D0 (no)	1995-05-16	Farmasöytiske formuleringer av ibuprofen
ITMI950961A0 (it)	1995-05-12	Composizioni farmaceutiche contenenti gemfibrozil
BR9307182A (pt)	1999-03-30	Composições farmacêuticas de 2-oxindol-1-carboxamidas 3-substituídas
BR9606066A (pt)	1998-09-01	Composto e formulação farmacêutica
FI973277A0 (fi)	1997-08-08	Farmaseuttisia valmisteita TNF:n estämiseksi
DE69117519D1 (de)	1996-04-04	14-o-p-chlorbenzoylaconin und analgetischer/entzündungshemmender wirkstoff